# A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis at Risk for Pulmonary Hypertension

> **NCT03267108** · PHASE3 · TERMINATED · sponsor: **Bellerophon Pulse Technologies** · enrollment: 145 (actual)

## Conditions studied

- Pulmonary Fibrosis
- Pulmonary Hypertension

## Interventions

- **COMBINATION_PRODUCT:** INOpulse®
- **COMBINATION_PRODUCT:** Placebo
- **COMBINATION_PRODUCT:** Open Label Extension

## Key facts

- **NCT ID:** NCT03267108
- **Lead sponsor:** Bellerophon Pulse Technologies
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-12-14
- **Primary completion:** 2023-06-09
- **Final completion:** 2023-06-30
- **Target enrollment:** 145 (ACTUAL)
- **Why stopped:** The trial did not meet its primary endpoint, hence was terminated due to futility.
- **Last updated:** 2023-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03267108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03267108, "A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis at Risk for Pulmonary Hypertension". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03267108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*